-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GuXR0L/MIQcBCJODX871OkNJXz2omjA/6/jHDdoUfs2HAk9IKDMgkMxYjVeDQkuu
 hJ+oOcOZpIGGCI3R/QR1FA==

<SEC-DOCUMENT>0000950123-09-015452.txt : 20090619
<SEC-HEADER>0000950123-09-015452.hdr.sgml : 20090619
<ACCEPTANCE-DATETIME>20090619155949
ACCESSION NUMBER:		0000950123-09-015452
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090618
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090619
DATE AS OF CHANGE:		20090619

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Geovax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			IL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		09901452

	BUSINESS ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306
		BUSINESS PHONE:		404 727-0971

	MAIL ADDRESS:	
		STREET 1:		1256 BRIARCLIFF ROAD N.E.
		STREET 2:		EMTECH BIO SUITE 500
		CITY:			ATLANTA
		STATE:			2Q
		ZIP:			30306

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c87080e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): June 18, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>GEOVAX LABS, INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>000-52091</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>87-0455038</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>1256 Briarcliff Road N.E.<BR>Emtech Bio Suite 500<BR>Atlanta, Georgia<BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>30306</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(404) 727-0971</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>&nbsp;</B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>


<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt; text-indent: 4%">This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time to time with the
Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward looking statements and information that
are based upon beliefs of, and information currently available to, the registrant&#146;s management as well as estimates and
assumptions made by the registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;,
&#147;estimate&#148;, &#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they relate
to the registrant or the registrant&#146;s management identify forward looking statements. Such statements reflect the
current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and
other factors relating to the registrant&#146;s industry, operations and results of operations and any businesses that may
be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the
underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed,
estimated, expected, intended or planned.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;8.01 Other Events</B>


<P align="left" style="font-size: 10pt">On June&nbsp;18, 2009, the registrant issued a press release announcing the execution of a proposal to discuss a cooperative
arrangement with Cook County Board President Todd H. Stroger and the Commissioner&#146;s of Cook County; the Cook County
Health and Hospitals Systems Board; and the Ruth M. Rothstein&#146;s CORE Center&#146;s Foundation. A copy of the press release
is attached hereto as Exhibit&nbsp;99.1.


<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>


<P align="left" style="font-size: 10pt; text-indent: 7%">Exhibit&nbsp;99.1 Press Release


<P align="left" style="font-size: 10pt"><B>SIGNATURES</B>


<P align="left" style="font-size: 10pt; text-indent: 7%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current
Report to be signed on its behalf by the undersigned hereunto duly authorized.


<P align="left" style="font-size: 10pt">Dated: June&nbsp;19, 2009



<P align="left" style="margin-left:46%; font-size: 10pt">GEOVAX LABS, INC.



<P align="left" style="margin-left:46%; font-size: 10pt">By:<U>&nbsp;&nbsp;&nbsp;/s/ Mark W. Reynolds&nbsp;&nbsp;&nbsp;&nbsp;</U>


<DIV  align="left" style="margin-left:46%; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mark W. Reynolds<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer</DIV>


<P align="center" style="font-size: 10pt">2




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="left" style="font-size: 10pt"><B>EXHIBIT INDEX</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="12%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="83%">&nbsp;</TD>
</TR>
<TR style="font-size: 10pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">3



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c87080exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">


<IMG src="c87080p87080_01.gif" alt="(HEADER)">


<P align="center" style="font-size: 10pt"><B>GEOVAX SIGNS HIV/AIDS VACCINE PROPOSAL WITH<BR>
HEALTH AND HOSPITAL SYSTEM OF COOK COUNTY, ILLINOIS</B>



<P align="left" style="font-size: 10pt"><B>ATLANTA, GA, June&nbsp;18, 2009 &#150; GeoVax Labs, Inc. (OTC BB: GOVX)</B>, an Atlanta-based biopharmaceutical company developing
human vaccines for diseases caused by the HIV &#150; 1 (Human Immunodeficiency Virus), and other infectious agents,
announced today that it signed a proposal to discuss a cooperative arrangement with Cook County Board President Todd H.
Stroger and the Commissioner&#146;s of Cook County; the Cook County Health and Hospitals Systems Board (&#147;Health System&#148;);
and the Ruth M. Rothstein&#146;s CORE Center&#146;s Foundation, (&#147;Foundation&#148;), that was founded by Cook County, Illinois and
Rush University Medical Center.


<P align="left" style="font-size: 10pt">Robert T. McNally, President of GeoVax noted, &#147;The proposed arrangement with Cook County through the Health System and
its CORE Foundation has the potential to advance the fight against HIV/AIDS by accelerating the clinical trials of the
DNA/MVA and MVA/MVA vaccines developed by GeoVax scientists, in collaboration with scientists at Emory University; the
Center for Disease Control; and the U.S. National Institutes of Health (&#147;the Vaccines&#148;).&#148;


<P align="left" style="font-size: 10pt">Cook County Board President Todd H. Stroger said, &#147;We hope this ground-breaking proposal, which is dedicated to
addressing the need to help eradicate the HIV/AIDS virus, will extend the opportunity for the residents of Cook County
and the surrounding region to participate in clinical trials of vaccines with the potential to protect against HIV/AIDS
disease.&#148; President Stroger added, &#147;This partnership carries out the mission set forth by our Health and Hospitals
Systems in providing state-of-the-art quality urgent healthcare to people. It will also assist in accelerating GeoVax&#146;s
vaccine program for treatment of patients infected with the HIV virus. We must always be prepared to adapt to the ever
changing needs of society while continuing to contribute to the overall health and wellness of our world.&#148;


<P align="left" style="font-size: 10pt">The proposal calls for the CEO of Health Systems to consult with the Director of Health Systems Institutional Review
Board and GeoVax to determine whether to present GeoVax&#146;s proposal to the Health Systems Board of Directors for the
purpose of obtaining authorization to negotiate an agreement with GeoVax regarding its proposal. If agreements adopt
the proposal in its present form, the initial effort of the cooperative program would be focused on accelerating
GeoVax&#146;s therapeutic vaccine program for treatment of individuals already infected with the HIV virus with the Ruth M.
Rothstein CORE Center conducting some of the clinical trials in Cook County. The participation proposed would contain
provisions for seeking and managing funds from private non-profit or government sources to pay for the clinical trial
program. GeoVax would bear responsibility for production of the vaccine supply, establishment, management and oversight of the clinical trials
process, and regulatory compliance, which includes interaction with government authorities. There can, however, be no
assurance that agreements will result from the proposal.



<P align="center" style="font-size: 10pt"><B>MORE</B>




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">





<P align="left" style="font-size: 10pt"><B>GeoVax Labs, Inc.</B>
<BR>
<B>Add 1</B>


<P align="left" style="font-size: 10pt"><B><I>HIV/AIDS Background</I></B>
<BR>
HIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America
where there are roughly 60,000 new infections each year. Globally, there are about 2.5&nbsp;million AIDS infections per
year, most involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3&nbsp;million people living with AIDS in North
America and 33.2&nbsp;million people living with AIDS worldwide. Presently, there is little to prevent HIV transmission
other than education, circumcision, and condoms. It is obvious from the spread of the disease that these methods are
not adequate. Existing treatments for individuals infected with HIV include anti-retroviral therapies that are
effective but have serious medical side effects and are very expensive (upwards of $1,500/month). This cost is borne by
the individual, third party insurance, local healthcare, federal or world health organizations. Development and
distribution of an effective HIV/AIDS vaccine holds great promise. The GeoVax Vaccine would cost a fraction of the cost
of current treatments and, to date, has not elicited serious adverse side effects. Like commonly used vaccines for
polio and measles, if the population was vaccinated with an effective vaccine, over time, the disease could be expected
to decrease in prevalence to a point where it might essentially disappear.


<P align="left" style="font-size: 10pt"><B><I>About GeoVax Labs, Inc.</I></B>
<BR>
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human
vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax&#146;s AIDS vaccine
technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in
uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the
person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics (treatment of people already
infected with AIDS virus).


<P align="left" style="font-size: 10pt">GeoVax&#146;s core AIDS vaccine technologies were developed by Dr.&nbsp;Harriet Robinson, Senior V.P. of Research and
Development, through a collaboration of colleagues at Emory University&#146;s Vaccine Center, the National Institutes of
Health (NIH), The Centers for Disease Control and Prevention (CDC)&nbsp;and GeoVax.


<P align="left" style="font-size: 10pt">GeoVax&#146;s AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN)
based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health
(NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines.
Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided
additional support to GeoVax AIDS vaccine development program with a $15&nbsp;million IPCAVD grant awarded in late 2007.




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">
<P align="left" style="font-size: 10pt"><B>GeoVax Labs, Inc.</B>
<BR>
<B>Add 2</B>



<P align="left" style="font-size: 10pt"><B><I>Safe Harbor Statement</I></B>
<BR>
<I>All statements in this news release, not statements of historical fact, are forward-looking statements. These
statements are based on expectations and assumptions on the date of this press release and are subject to numerous
risks and uncertainties which could cause actual results to differ materially from those described in the
forward-looking statements. Risks and uncertainties include, but are not limited to, whether (i)&nbsp;the Director of the
CEO of Health System (after consultation with the Director of Health System&#146;s Institutional Review Board) determines
whether to present the GeoVax proposal to the Health System&#146;s Board, (ii)&nbsp;that the Health System Board will authorize
Health Systems to negotiate an agreement regarding GeoVax&#146;s proposals, (iii)&nbsp;an agreement can be reached, (iv)&nbsp;Health
System will request that the President of the CORE Foundation Board of Directors present the proposal to its Board in
order to seek authorization to negotiate an agreement, (v)&nbsp;if an agreement is reached with CORE, whether needed funds
can be raised, (vi)&nbsp;the proposed clinical trials will prove helpful to GeoVax&#146;s efforts, (vii)&nbsp;GeoVax can develop and
manufacture these vaccines with the desired characteristics in a timely manner, (viii)&nbsp;GeoVax&#146;s vaccines will be safe
for human use, (ix)GeoVax&#146;s vaccines will effectively prevent AIDS in humans, (x)&nbsp;vaccines will receive regulatory approvals necessary to
be licensed and marketed, (xi)&nbsp;GeoVax raises required capital to complete vaccine development, (xii)&nbsp;there is
development of competitive products that may be more effective or easier to use than GeoVax&#146;s products, and (xiii)
other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking
statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements
involving certain risks and uncertainties including, without limitation, risks detailed in the Company&#146;s Securities and
Exchange Commission filings and reports.</I>
<BR>



<P align="center" style="font-size: 10pt"><B>###</B>




<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>c87080p87080_01.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 c87080p87080_01.gif
M1TE&.#EAO`)7`?<`````````_Y"MOI&OOY*PP):SQ)VZRJ;!SZS%T[+*UKC.
MVKS2WL+5X<;9Y,K<YL_?Z-3CZ]KF[=WI\.'K\N3N\^CQ]>OS]^[U^/#V^?+W
M^O3Y^O;Z^_?Z_/C[_/G\_/K\_/[^^_S]_/___/[^_C,`;5P`,G,`36T`:68`
M=&0`+FP`;```````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````!+8X!A0F)-T\A+8Q!F;
M^````!4``-$`&@`1$%L`&0`1#P```````1F5:````!A;,!+9I)$`724>G```
M````````````````````````````````````````````````````````````
M```````````````````````````````````````````````````````0O1+6
M\#X`/!4``)#I()$[L/___Y$[IY$#(R4>G````````(H`X!+9A!+:*!+<4)#I
M()$#*)#?&I&://___Y%8I)?O!!+B+)?NR!+:-!+:(```&````!+9^```0```
M`````!+:-!+:(````````8H`X!H`1!F;^"4>G!+<O&5%F`)P```#;``"P```
M`````#X`/!+:,(H```$``SH`0U<`7$X`24\`1%,`5W,`7',`>64`=#,`;5P`
M,G,`36T`:68`=&0`+FP`;```````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"P`````O`)7`0`(_P!+"1Q(L*#!@P@3*ES(\*`&
M`P(2-)Q(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JC2IH4*%"1(D1(@`P<$#
M!SASZL0)86;,"1<N:#`8@0"!"2N3*EW*M*G3IU"C2IU*M2I'#1A>0GC08$$"
M!`<,%!AK5(#9LVC3JC5KE,#8`P<2+-"00``"#$*MZMW+MZ_?OX`#"QZ\4,,$
M"%T3A"U`8*T`MP4,&$"`($$"!7(9-&B@F8%GSIX7+,#\5;*!L@<<%!#@(&S<
M!0T@3+!`N+;MV[ASZ][-VV/+!@A.-W;L5C*"!;(M8!CZ$6N%"!,0"#``83A:
MMP<:5&#>N[OW[^##B_\?/_%"A`9?&5MG&SDN@P?0,22EL#J!X0@.O`8?<);`
M@>,15$#>@`06:."!")*$000+!+<>6Y,MX(`$%<CWU`*/1>!0!34IQIA9D2%W
M08(DEFCBB2CF5H$##K+%EG\*3&CA5`_9-=%S#B1P&H@(-(!4BD`&*>201'YT
MP0*K/5:6608D(,%2W"U4E``,7&18`M81@,"317;IY9=@FCB!CHV5R20"#@AH
MD`80,/`597`>4"5'$/SWP$(8'J71B@HD68`"/X8IZ*"$%AI8!%B^6.8!$*AY
M4)V.G15H1AH<,%V4!54`D0,>7<!BF0E`8.BHI)9JJDD7U/68D@(4$*I"&##_
MT%@!"#"PDTT)3)K1!)LFY,!T,WI$`9)F)>#HJ<@FJ^RR`UG:5ED$B+J0J@9P
MZ1"F&6$H$4+2;2M2!$D>@"VSY)9K;I`5U/6L409HN%!U`AR@:TE%%7#L0!"L
MYNY(%2S0&`+SGBOPP`2'5^.SCRUPKT.6%D!!4I;.25"EEY[D0&,&C%OPQAQW
M#%@#BC;F[4(/-,:I188]`-_"`FE`4T\67DS`O@)-.><%B,5F`8,._`;;O1=T
MY6-"#9CL\=%()TV5NFX]5@!M#6%H`,L*\9IE`P9=@,!P!+1;"@:K+5!0G@\W
M`-%9!H`LP`,=7&PC01@*`('&I=0XLM)XYZWW2-(A_XP`175)/-`%+@7E$G<1
MG#T66V+C:ZG3C'=0EP$SUBBNOR">+1:5';3]V,FE$"LX0K+^O??IJ*=N49Y&
MA3T1Q:`+I*-IILE;R@6K&>#`!,_%??*4NE-@GG2L16"6M*5`8!9.9B$0H'G.
M$N!`YQW$C?64=R-T`0&-J^[]]^#3IV1C"KQN:>P3/'B6V'4A0#WUO\I=BG0&
M4/"^Y*U&]_;\=EG=P/T6(-[TJ-<W!T#$`"-BR`.F!KX&.O!T_FK+=`!')8),
M8`$3F,D$,@B1!E``(A&X7^<@HH`*-(8!(J385HPB(/'%9#HB;-L)WS<!%[&F
M(0\9W0-WR,.-N:U,R,/3=/\<M1R#2*<!)9L:]9XS$TLEH"@SBR&&&*`!Z7#J
M`9?ZE0)B6('5#)!Z#%@-`1I`-X(X@(P]3*,:!P:!LTTG8$1I3/>X)0#.7*IS
MFDI+J%H50A%J,7GQ"J``Q,:`0<;0`EZ\WP<?$T2$:,`!-%NC)">)K'Z=C7ME
M%$C?(EF0(^;K*)TK"NVHD[YHQ?"(=3O-`5@(2/>)T&;OT]2S8F<0"_".DKC,
MI:DPH"J[9%)Y0TP(*B&R@,Y-@&T:2&;G:N3*][G-77EZFPD)(`$1J@J%U%/5
M`B!"@(<Y4I?@#">A'HF`U3BOC'$[0`2"-1!4_JH`?8QA]3[WOL15K!13NJ$F
MIQ/_SPY\4GK4FX`Y2Q&_NV52G`A-*)!6=)JT42UY28K09F"SS3KN,UZVVDD(
M,?"X6J&G3-8JA:4H-Q"!/B8!#&B0=09HN1]A#H,2F``%+'0!:SV'(@R`(T,F
M8).##@0_%=F@0(3ZD:TH]*@[I,`#%'"<![!L3$E2BQP%DBHSI86:7VM`5!_C
MO(+\:HZED$`YKZ,C0Z9K.@D4",@,("*"5$=#FLI>0A;@S=4=P"LZ)0HM%=)%
MB>`.K!MQ@*@4`%BD&O9T"P).KK#%(;#`Q0"/A>R,>!H6R%J6K0.I``/"XJ2#
M5,!V!AD39#&(3[@TH+*<#-!!BB*JBQWF.%!##];ZE2N<__F30Q)C`,`$\H`>
M#40#!;C30(`C+?A(Z$D6T(X$1M0`"2R`2Q)(P(0"9;P[U=`!.!,(!"Z``<%>
M;P'R255G,?"`8;DK`I[R#P2D!93#NG=O-5UOHS"%%0S8][YX,0A>N(O?M+8L
M+PAA9T&*^-N@!$7`?"7`G="4O&W.14=R25QE&(2`AU0FN*70[38/DQVLM=,`
M+JT5P"PPVKB$[@`44&=<P[+!)ND(=,I+P%*IF:.OR6N!$$Y``<36K^!P4`%P
M68XZL82F`\BGPN]-\MXT0#@+^)0W#XG-`;1;)P2T\0*=BXL&1IB`"QA@P0J0
MP!BK(Z'Z9>J(Z6MN:MJ(%*9.`/_%FK+D<^1FF0Y08&8#\9=<3H,!!O.*HQG3
M\07<5(K#@.P\&?,R!]G4S0Z`N$Y*CK2DIQ*7KLJ%5Q(Z`/5TAT?I)4Z3^?GR
M>BO0M@+0$KA6ILYZM68`@8@5I:7%0)-*43)>L8U7W*&,)BNLSM`A8'O_.P#;
MI!L!=<IJ3%CC5;K^I@`#=.XR79VTM*>=%.F8CJT@VYV6,*B`B$!2`!+8[-<*
M(`'Z-"!`&&C`5_/LE3IJJKD1T``!MH7(C(4N`7>ND@((0)>TA>6W`G`7GB>#
MI048#P)@(S5UMEDG>WV9H$;F'O_8!C+34?OB&!\)B]P%@02@YTFM^76ZLA/=
M[MX)`PK_&`J+\,W+XSCJM-)5.67F]L2624@@@DV7ALY8BGXI]K?&JEO0>[L`
M!L346!B8BP86(!31=.5(`JH)732$J/]A4;@9S[K63]23-F)=*:TI[-;'3G;Q
MY`<Y35GZ7LO.]K:[_>UPC[O<YT[WNMO][GC/N][WSO>^^_WO@`^\X`=/^,(;
M_O"(3[SB%\_XQCO^\9"/O.0G3_G*6_[RF,^\YC?/^<Y[_O.@#[WH1T_ZTIO^
M]*A/O>I7S_K6N_[UL(^][&=/^]K;_O:XS[WN=\_[WOO^]\`//E(!0'P`E,+X
MPD]^WI`O$.)7A/D3@;[RIP\DZ1__^1:Q/O6W3R+M#Z3XWS\^__*+/W[G?]_\
MY+\^]]=_(.\?GWK&![_ZF4__YH=?_>S/OX'<#P#XV___VC=^!N%^^E>`W<%_
M_H=_`GA^Z#>`!OB`XF%]XY>`]:>`%.B`$)B!W@%]]'>!`'A]_=<Y"SA_^*>!
M)H@;Z4<0\@=^+$A_*2A_XO=_)SB#-%B#-GB#.)B#.KB#/-B#/OB#0!B$0CB$
M1%B$;4>`1IB$)"&!"$%^3AB#&I%^2*B$2<B$!U&!))@1'#B%5$B$_2=]WH>%
M(YA]&-B%9MA\';"%YM>$#@B#S;>&*GB%*@B'\8=^:UB'!0&#=>B"Y3>&9QA[
M(<B!#"&!8IB`<:@0(9B&;^B"X5=\(O]X?R!XAY!8@G\X>XDHB`MAA0#X/IIX
MA?<SAIB8B(JH@#)(BI-8B;(GBEB8$)W8AVY8B@/XB:48BIPXAZ!XB%R(BJCG
MA)*8B668A:R(B+)8@K1HB($XB[BHB[1GA5/8BK`HAWF(AK5(C+@XC9>(C'&8
MB\I(>@'X@6P8C9"XBH<XB\8XCO-GC")XBW.XC8#HAKP8ABDH?GW(@(CXBO)(
MC_=XC_&HCR\(AY2HC>Q8B0`9C`%9D`TQD-]HD`J9D%&XD`XY@/[X?!'YD!19
MD19YD1B9D1:)D'R!B1K)>N]XD!SYC/EXA1-9DO)XDG<XDA^Y>:IXD`W9A`'8
MC+\(C239DJ?_)XJCB(@Q:9(^F8E@Z(NGB).[.(SX:'\1J8<QN(^-&(U@2(?4
M>)11N8(G292:]Y(J:(S'^'W^UX*4F(U..8X5*(;A*);F:)6>]X19:8ULZ8%#
M>7]C.8EC.8)D699OB997^8PZ.8$4J)9!^8UQ>9.!>90>"8QXF9:GN)?2^(A?
M^8\$"8)V^8OQMY:K&(J'"7J%J9COYY9GR7]-*8-AF(<=R)A1^9F7V7F%N9D[
M>8UV^9?.*)>1&8[I")OK>)J<IY8E^8KV2)5J*)HKN(@KZ8H>Z96\"8ZV^9$L
M>9RHF)S*>8;,V9Q4:(_0.9W469W6>9W8F9W:68,!0!#=21$!$)[A_[F=:42(
MW6B2\;B/O"B3YLF`NYD;XRD0\<D0\UD*]4F>X../K'E^-NF-4/B7>6B(JCF9
MYBB=@_&=\MD0"%H0"XJ?JO.%:TF:[\>%ZEB3JKF:1CF4S_D4"]J@!S&?X]F=
M]^F@IP.A7#F-$SJ(#/F6FJF9+%J/@AB1(OJ=,TJC]2F>`U&CWGFCWBF?\8FC
M]IFCG?.C.VH00)JC(!JB26JC->JA]GF?1QJD0!JE)/H76[F8C'FECWF6+#J,
M+DJ2")BES@>'."J>29JC"9J@1TJC:)JF;MJA/BJ?U(.@=#JD/SJG0CJD;1JD
M;]JG'[JG`8"G3TJG=%JE@+&?%ZJ(B+JB@O_IB2B*E2_JJ)S)H)2ZIU+:HWR:
MIH7JIID*IYTJJ'P:J((JJGIJG_?#IG[:J9E:J9IZJISJJ8;:D2B:J,0WJ_UY
MEV&8H4P9FI*:I0G1H+!ZJ4:*J3ZZJ:_JIZ3:`9N:K$PZI:ZJJCL:K*SJG<\:
MK$X:JU/QCGP)?]JZI3?9F+1ZJ[P:B];XJ],*ITX*JZ)JK*N*JJ$ZIS::I^R:
MIZ`JH@Q:JG'ZIT9:K<2ZJMC:%QQHJ^":F#S9J^?)I8+II>;:K^BJKZV*K])J
MKP^KK)8:I>GZK,(JIQ#+J99*KZ5JK?]ZJ`$JH=_JF`4JC"3[E9[9A.6($,#*
ML,B*J>O*KL#JJ8'_.J7]2JQUBJ\<.[/'.JQO6J\P&[)^T9Z2:9S`J9^228<3
M"8_\%YP?NJ3%.K6#2K5EJJ15F[4=JZ-K.J@6"Z4C6K--RJ3^2J5K^J-H>ZU$
M*W@>JK:?"JIK"X'IZK(>2[%QNWEFFK=ZN[=\V[=^^[>`&[B".[B$6[A]>[>$
M1Z4,FK=&JKB(^[B0&[F2.[F46[F6>[F8F[F:N[F<V[F>^[F@&[JB.[JD6[JF
M>[JHF[JJN[JLV[JN^[JP&[L8MZ%"Z:T;`9"TVQ2Y*[NVT8GNB9M1D93K.8@$
MN+OLR90?496\2R"^VYE5D:L":KL(NX0"ZQ'&N[R!8:)W.;!2`;W1>ZM(_WL2
M7YJ\V-M].YF2X(N,[BB)N@F54NF]).N.M@B<B0F5Z]NT&8J2N0F%;VB*Y3L@
M6KJR"LB'<-F(O6B*!RR.)QJ_+8O`M;F8\^B?`6BK^UE_7KF9RON_WX&H3RN_
MM#F8AEF7_NN;^OFHK6F<+9J,,.J."NN?6'J]&KP7D"K`F5F@#5C`XGK`X&B>
M2CF_)ANNI5F5+OJEOQFAYQO#$3B\`SNN0>RK."R9I#FN`(JT6PF@*4RPO9JE
M1EG%(YNR2+S!&"C`5%R-3NS"8MG`8XRK"^R'H\F9S9NHH]BBDPJI7PP>Y^F'
MX%K#&%RA(AR("HR-D3F:-PR*:$R761RP43R;*O^;CC!<QT^AGDJ<M+ZYB)3<
M@L5)R9A,G/J9GE";R6.ZAY@<RL6)O-TZR?0(O/W[QXZ\RJS<RJ[\RK`<R[(\
MR[1<RX>7FK:\>*@LD1>QR]:;RY/VG"/9R-P+S`HES%IH$L1LS`\*H[98F3YL
MH=%\R?F(O,Q\S*SHEF+8Q@=+KJMYQF5\S8<%OW@\E=4+OW%,QN$LSL-WO"N9
MQI&,JUL,FG[)SN[%A,5[LL6LLD`,C-ULS]@<E@4[E2KJE+HZPML+T+IDQ4\,
MS:`IKFLLFBALQ@J-2]K:F_3KR01,PL`KG4:KOQ4-><L<TH(WTB3]=R9]TGQG
MH"K=TB[]TC`=TS)M@[C_.]-[X\N_'(7Q+),#;=/-K,P=0<?2F]`^K33++,SY
MF[Y$7=1(8\%0JX=,^\E1G8T33,'NJ]&5:;]1G=),;<>B',C:#(NL><%&#(8-
M#,)WV)>#R=5=O8&TB<#E2L4M[,Y=_,T/;;)73-%M;2@.C<"X>=5`G,\J^]>F
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MVSTLE1H*V+NIM!SMM-!NX2+NN&TKM22NH\7:X2"*Z,H>K8O+YAB.X`DN).@.
MM/>=[DJV[NP^K>[>0X9;[_9^[_B>[_/^)8Y;$7J[[P`?\`(_\`1?\`9_\`B?
M\`J_\`S?\`[_\!`?\1(_\11?\19_\1B?\1J_D9$:X2/!UAM?&_>[R=XMD6/*
M$1D<\BGRQHU9T^M]NRI?V[+_WO+8U^D4`?(Q/QB:'<3TZXI@NL/Z.^W_&*.]
MC;X9G?.$D=K\V\<OW]V$>>O2V.(N3IP-/=M(+QCE!\CJ.//]^\%ECH[P%[]/
MO-17WY%C;\$";?-63]F;#O8BZ,50[?1EC_5@&8Z;#.9`#Y=?G^1O_^!BO]US
M#[!RC]9B#='FW)9)?N0,_.`>'_C/J]_^>]I=[\+<3)GH%T-F_=IWK<J.?]VW
M;<E).X_OV8\1#-(G'_HN/K]2S8<XW_E!(M2NKT;C&_OE6;VTWT/6?/NZO_N\
MW_M.P?DY'7V^WQLL3=Q-+Y(X+?>-/_RZT;0NGWVV#_ADS_R].Y,U#_W1G]"M
M3_TH_['SC`WMIT^,*OGGTO[;XBB_(\_]C^R8_2W(66_U"WS$NN[`33_6O0C\
MZB^^FQ__E,WT$*F;`-%!8`<`I0P6/&BP%$*$"AL"&"B0H<*%"2E>Q)A1XT:.
M'3U^!!E2Y$B2)4V>1)E2Y4J6+5V^A!E3YDR:%R=:?`A`I\Z#$1_:Y(GQ)L6=
M.QT"'6IQ842"2BL>;%A3ZE2J5:U>Q9I5ZU:N7;UN_/G3J4.?1\DV%6I6K4VB
M$L<^9)HTZM.O=>W>Q9M7[UZ^??6&53NWYT"Q2]VF72M8*<3#<^&6I1MYK%_*
ME2U?QIQ9\^:243T3#2PQZ..@;-?2+<QX-,ZVAR,/5<Q9]O]LVK5MW\;-L>C-
MW0Y+0WUJ="'/W[VAYD1^?/APAL5+"S=:-/=TZM6M7\>>7?MV[MV]?P<?7OQX
M\N7-GT>?7OUZ]NW=OX<?7_Y\^O7MW\>?7_]^_OW]_P<P0`$')+!``P]$,$$%
M%V2P09`"P"H`"25TL$(+OY,.,=]^`\LQH3C,:#3CF'-,.,HHK`I%@U2\L$47
M<<N)J.)\TTTP#AE#*\3"6`-NL=CR@I"J(#$:\D4CCYS-1M!.6]*F'`USS32P
M0DS,LB)I4I%""%E$LDLO^U+LQ]C&?!+'*">3LDD-D0(-Q"U9G##(-Z^<D,@M
M*8*SE"SAK'/%/O54*`"!4)133T+_#YW3T$3K_!-/+AM-5-$O)UUP3(W(--$P
MS^)R,E,UT005Q^8*^NW/0E>4%-45!RI2T`ZR'#3.-P%5=<A3:264U4!3-717
M6G^UU==?\136U5?]M#582I<ET--0+Q5UL#(YE9$P*F6T5"AJ?VQ556)]-7;0
M5775,R)7Z0272'7'/;;6;]WU5EE@UZV5J5N'O9)9??T#,4RPXC)S4\C.LO93
M&M-LK6!NW\T37'O9;3?<<S,RE<YNRR47UW?GO1/=CBFF^&%\-]ZW9/Z41-A)
MGW:#CEJ"SQ0SY9?16EC8>+\--V)S`QTT8Y[;M?EFC%^5\]Z+`?V8V*0ORG=H
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M``4X0`(6T(`'1&`"%;A`!C;0@0^$8`0E.$$*5M""%\1@!C6X0?\.=M"#'P1A
M"$4X0A*6T(0G1&$*5;A"%K;0A2^$80QE.$,:UM"&-ZS1B$9$HM8Q9T.C\U3I
M6$:Z&_7K0RPCU1"1$D0EJDZ),HO.AD2'0RJBY#-0BE+`NB8CH'#1BU62UI,D
M,YG4.,5O@;OB&,U(N,"D48U5A"-(;/2X'&F1C14!S%'R:#4LEDE;,9/9U<28
MK36%:)"IBV,BK;@8.C[F3'U#S6LBR37'/&Y'/0'DDL2DM>`$,BEM&1QB?J1(
M4A[1D0/;(<)(I<<VL1);E709+,7(I"DNT49!A%;KHO7%5Y;2EQV!32/-,DI*
M=G*8QCSFUPYW-4(F\UI\"Z4F#?G(Y4BA\Y?7+&0?EPDJR4Q$+@GY))EB:<LM
M>DU*5?-D#GLH26RV,V5FPMHE/^7-->*Q<)IT&3NMALXQRK.8U@S,.1%I3G?"
M\8Q_<^,\`[K0;C;)CF#<YYI.UU"&1A*B/KKH*`N*0V?Q$'6O>QUT7"=2'Q)1
M1+6,CA"=XYDG_G"D382I<40GG22R-)4;Q6E.=;I3GO;4IS\%:E"%.E2B%M6H
'1]U?0```.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
